Skip to content

Antares Pharma, Inc.: 10-Q filed 2017-11-07

What Antares Pharma, Inc. reported in its quarterly report filed 2017-11-07 (fiscal Q3 2017): 37 published measures, 94 facts as tagged in accession 0001564590-17-022312.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-07
Fiscal period
fiscal Q3 2017
Accession
0001564590-17-022312 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Antares Pharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-3078,470,167USD
At 2016-12-3166,325,450USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-3042,473,548USD
At 2016-12-3121,106,916USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-3035,996,619USD
At 2016-12-3145,218,534USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-3027,433,489USD
At 2016-12-3127,714,588USD
At 2016-09-3028,781,427USD
At 2015-12-3132,898,676USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-5,452,521USD92
2017-01-01 to 2017-09-30-13,028,382USD273
2016-07-01 to 2016-09-30-6,120,983USD92
2016-01-01 to 2016-09-30-19,838,556USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-09-30878,855USD273
2016-01-01 to 2016-09-304,278,643USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-07-01 to 2017-09-3015,052,397USD92
2017-01-01 to 2017-09-3040,476,015USD273
2016-07-01 to 2016-09-3013,478,763USD92
2016-01-01 to 2016-09-3038,025,925USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-266,570,874USD
At 2016-12-31-253,445,306USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-3017,296,719USD
At 2016-12-3117,867,412USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-09-302,371,453USD273
2016-01-01 to 2016-09-301,886,823USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-4,945,810USD92
2017-01-01 to 2017-09-30-12,431,256USD273
2016-07-01 to 2016-09-30-6,136,445USD92
2016-01-01 to 2016-09-30-19,896,869USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-3058,393,530USD
At 2016-12-3145,264,468USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-07-01 to 2017-09-30625,938USD92
2017-01-01 to 2017-09-30794,129USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-3017,482,334USD
At 2016-12-3119,906,916USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-09-308,245,154USD
At 2016-12-317,884,983USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2017-09-301,095,355USD
At 2016-12-311,095,355USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2017-09-301,630,785USD
At 2016-12-312,044,608USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-09-3010,146,966USD
At 2016-12-319,073,173USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-3011,475,310USD92
2017-01-01 to 2017-09-3032,548,219USD273
2016-07-01 to 2016-09-3011,581,487USD92
2016-01-01 to 2016-09-3035,795,234USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-09-307,942,376USD
At 2016-12-315,326,962USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-306,529,500USD92
2017-01-01 to 2017-09-3020,116,963USD273
2016-07-01 to 2016-09-305,445,042USD92
2016-01-01 to 2016-09-3015,898,365USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2017-07-01 to 2017-09-308,522,897USD92
2017-01-01 to 2017-09-3020,359,052USD273
2016-07-01 to 2016-09-308,033,721USD92
2016-01-01 to 2016-09-3022,127,560USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2017-07-01 to 2017-09-308,185,865USD92
2017-01-01 to 2017-09-3023,013,130USD273
2016-07-01 to 2016-09-305,622,937USD92
2016-01-01 to 2016-09-3020,240,635USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-07-01 to 2017-09-303,289,445USD92
2017-01-01 to 2017-09-309,535,089USD273
2016-07-01 to 2016-09-305,958,550USD92
2016-01-01 to 2016-09-3015,554,599USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-30156,425,904shares
At 2016-12-31155,167,677shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-09-30-700,695USD
At 2016-12-31-714,270USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2017-09-3026,062,500USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-3053,778USD
At 2016-12-3153,607USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-09-306,394,379USD
At 2016-12-315,872,846USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-09-301,680,208USD
At 2016-12-311,376,299USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-5,456,142USD92
2017-01-01 to 2017-09-30-13,014,807USD273
2016-07-01 to 2016-09-30-6,118,351USD92
2016-01-01 to 2016-09-30-19,846,376USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-01-01 to 2017-09-301,520,197USD273
2016-01-01 to 2016-09-301,371,538USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2017-01-01 to 2017-09-3045,600USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-07-01 to 2017-09-30119,227USD92
2017-01-01 to 2017-09-30197,003USD273
2016-07-01 to 2016-09-3015,462USD92
2016-01-01 to 2016-09-3058,313USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-301,069,614USD273
2016-01-01 to 2016-09-30624,232USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-302,615,414USD273
2016-01-01 to 2016-09-30999,158USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-30701,704USD273
2016-01-01 to 2016-09-303,308,607USD274

Inspect the source

Entity
Antares Pharma, Inc. / CIK 0001016169
Captured
SEC response SHA-256
540b8a117c7898b4d835a42d9aec42c261c74ea0da49d4755fcc6f2d9b68be71

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001016169.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))